[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 629,413
  • Shares Outstanding, K 90,563
  • Annual Sales, $ 30,910 K
  • Annual Income, $ -209,470 K
  • EBIT $ -160 M
  • EBITDA $ -159 M
  • 60-Month Beta 0.26
  • Price/Sales 20.65
  • Price/Cash Flow N/A
  • Price/Book 7.57

Options Overview Details

View History
  • Implied Volatility 171.31% (+39.26%)
  • Historical Volatility 66.22%
  • IV Percentile 25%
  • IV Rank 13.56%
  • IV High 755.94% on 03/03/26
  • IV Low 79.60% on 05/18/26
  • Expected Move (DTE 8) 0.68 (10.19%)
  • Put/Call Vol Ratio 3.01
  • Today's Volume 341
  • Volume Avg (30-Day) 520
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 19,302
  • Open Int (30-Day) 17,650
  • Expected Range 5.99 to 7.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.44
  • Number of Estimates 2
  • High Estimate $-0.42
  • Low Estimate $-0.46
  • Prior Year $-1.35
  • Growth Rate Est. (year over year) +67.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.28 +26.33%
on 07/14/26
7.18 -7.09%
on 08/11/26
+1.30 (+24.21%)
since 07/13/26
3-Month
3.43 +94.46%
on 06/25/26
7.18 -7.09%
on 08/11/26
+1.95 (+41.31%)
since 05/13/26
52-Week
3.43 +94.46%
on 06/25/26
11.24 -40.68%
on 09/05/25
-1.35 (-16.83%)
since 08/13/25

Most Recent Stories

More News
Verastem: Q2 Earnings Snapshot

Verastem: Q2 Earnings Snapshot

VSTM : 6.67 (-4.03%)
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375...

VSTM : 6.67 (-4.03%)
Verastem Oncology: When Your Earnings Call Gets More Attention Than Your Pipeline Ever Did

Barchart Research What to Expect from VSTM Earnings VSTM Generated August 5, 2026 Current Price $5.87 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 7.67% Verastem Oncology: When Your Earnings...

VSTM : 6.67 (-4.03%)
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort...

VSTM : 6.67 (-4.03%)
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference...

VSTM : 6.67 (-4.03%)
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

TARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer A cohort in TARGET-D 202 will...

VSTM : 6.67 (-4.03%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock...

VSTM : 6.67 (-4.03%)
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Broad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor...

VSTM : 6.67 (-4.03%)
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue...

VSTM : 6.67 (-4.03%)
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

TARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D...

VSTM : 6.67 (-4.03%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 7.36
2nd Resistance Point 7.21
1st Resistance Point 6.94
Last Price 6.67
1st Support Level 6.52
2nd Support Level 6.37
3rd Support Level 6.10

See More

52-Week High 11.24
Fibonacci 61.8% 8.26
Fibonacci 50% 7.34
Last Price 6.67
Fibonacci 38.2% 6.42
52-Week Low 3.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.